Release 5
WorkflowThis page is part of the FHIR Specification (v5.0.0: R5 - STU). This is the current published version. For a full list of available versions, see the Directory of published versions 
. Page versions: R5 R4B R4 R3
| Clinical Decision Support Work Group | Maturity Level: N/A | Standards Status: Informative | Compartments: No defined compartments |
Raw JSON (canonical form + also see JSON Format Specification)
Chemotherapy Regimen
{
"resourceType" : "PlanDefinition",
"id" : "KDN5",
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n \n <table style=\"width: 100%;\">\n \n <tr>\n \n <td>\n \n \n <div style=\"width: 200px; height: 100px; vertical-align: top;\">National Comprehensive Cancer Network</div>\n \n </td>\n \n <td>\n \n <h3>Chemotherapy Order Template</h3>\n \n <h1>Kidney Cancer</h1>\n \n <h2>Gemcitabine/CARBOplatin</h2>\n \n </td>\n \n <td style=\"text-align: right; vertical-align: top;\">KDN5</td>\n \n </tr>\n \n </table>\n \n <table style=\"width: 100%; border-top: 1px solid; border-bottom: 1px solid;\">\n \n <tr>\n \n <td style=\"width: 33%; border-right: 1px solid; vertical-align: top\">\n \n <h4>INDICATION:</h4>\n \n <p>Metastatic or Relapsed – Collecting Duct/Medullary Subtypes</p>\n \n </td>\n \n <td style=\"width: 34%; border-right: 1px solid; vertical-align: top\">\n \n <h4>REFERENCES:</h4>\n \n <ol>\n \n <li>\n <a href=\"http://www.example.org/professionals/physician_gls/PDF/kidney.pdf\">NCCN Guidelines® for Kidney Cancer. V.3.2015.</a>\n </li>\n \n <li>\n <a href=\"http://www.ncbi.nlm.nih.gov/pubmed?term=%22The+Journal+of+urology%22%5BJour%5D+AND+1698%5Bpage%5D+AND+2007%5Bpdat%5D+AND+Oudard+S%5Bauthor%5D\">Oudard S, et al. \n <em>J Urol</em>. 2007;177(5):1698-702.\n </a>\n <sup>\n \n <a href=\"http://www.example.org/OrderTemplates/PDF/appendix_E.pdf\">a</a>\n </sup>\n \n </li>\n \n </ol>\n \n </td>\n \n <td style=\"width: 33%; vertical-align: top\">\n \n <h4>NCCN SUPPORTIVE CARE:</h4>\n \n <ol>\n \n <li>\n \n <i>Emetic Risk:</i>\n \n <table>\n \n <tr>\n \n <td>Day 1</td>\n \n <td>Moderate</td>\n \n </tr>\n \n <tr>\n \n <td>Day 8</td>\n \n <td>Low</td>\n \n </tr>\n \n </table>\n \n </li>\n \n <li>\n \n <i>Fever Neutropenia Risk:</i>\n <br/>\n Refer to \n <a href=\"http://www.example.org/professionals/physician_gls/PDF/myeloid_growth.pdf\">NCCN Guidelines for Myeloid Growth Factors. V.2.2014</a>\n \n </li>\n \n </ol>\n \n </td>\n \n </tr>\n \n </table>\n \n \n <h4>CHEMOTHERAPY REGIMEN</h4>\n \n <p>\n \n <i>21-day cycle for 6 cycles</i>\n \n </p>\n \n <ul>\n \n <li>Gemcitabine 1250 mg/m\n <sup>2</sup> IV over 30 minutes on Days 1 and 8\n </li>\n \n <li>CARBOplatin AUC 5 IV over 30 minutes on Day 1</li>\n \n </ul>\n \n </div>"
},
"contained" : [{
"resourceType" : "ActivityDefinition",
"id" : "1111",
"status" : "draft",
"productCodeableConcept" : {
"coding" : [{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"code" : "12574",
"display" : "gemcitabine"
}],
"text" : "gemcitabine"
},
"dosage" : [{
"text" : "1250 mg/m² IV over 30 minutes",
"timing" : {
"repeat" : {
"duration" : 30,
"durationUnit" : "min"
}
},
"route" : {
"text" : "IV"
},
"doseAndRate" : [{
"type" : {
"coding" : [{
"system" : "http://terminology.hl7.org/CodeSystem/dose-rate-type",
"code" : "ordered",
"display" : "Ordered"
}]
},
"doseQuantity" : {
"value" : 1250,
"unit" : "mg/m²"
}
}]
}]
},
{
"resourceType" : "ActivityDefinition",
"id" : "2222",
"status" : "draft",
"productCodeableConcept" : {
"coding" : [{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"code" : "40048",
"display" : "Carboplatin"
}],
"text" : "CARBOplatin"
},
"dosage" : [{
"text" : "AUC 5 IV over 30 minutes",
"timing" : {
"repeat" : {
"duration" : 30,
"durationUnit" : "min"
}
},
"route" : {
"text" : "IV"
},
"doseAndRate" : [{
"type" : {
"coding" : [{
"system" : "http://terminology.hl7.org/CodeSystem/dose-rate-type",
"code" : "ordered",
"display" : "Ordered"
}]
},
"doseQuantity" : {
"extension" : [{
"url" : "http://example.org/fhir/AUC-dose",
"valueInteger" : 5
}]
}
}]
}]
}],
"identifier" : [{
"system" : "http://example.org/ordertemplates",
"value" : "KDN5"
}],
"version" : "1",
"name" : "GemcitabineCARBOplatin",
"title" : "Gemcitabine/CARBOplatin",
"type" : {
"text" : "Chemotherapy Order Template"
},
"status" : "draft",
"experimental" : true,
"publisher" : "National Comprehensive Cancer Network, Inc.",
"description" : "Gemcitabine/CARBOplatin",
"useContext" : [{
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString" : "A"
}],
"code" : {
"system" : "http://example.org/fhir/CodeSystem/indications",
"code" : "treamentSetting-or-diseaseStatus"
},
"valueCodeableConcept" : {
"text" : "Metastatic"
}
},
{
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString" : "A"
}],
"code" : {
"system" : "http://example.org/fhir/CodeSystem/indications",
"code" : "disease-or-histology"
},
"valueCodeableConcept" : {
"text" : "Collecting Duct/Medullary Subtypes"
}
},
{
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString" : "A"
}],
"code" : {
"system" : "http://terminology.hl7.org/CodeSystem/usage-context-type",
"code" : "focus"
},
"valueCodeableConcept" : {
"text" : "Kidney Cancer"
}
},
{
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString" : "B"
}],
"code" : {
"system" : "http://example.org/fhir/CodeSystem/indications",
"code" : "treatmentSetting-or-diseaseStatus"
},
"valueCodeableConcept" : {
"text" : "Relapsed"
}
},
{
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString" : "B"
}],
"code" : {
"system" : "http://example.org/fhir/CodeSystem/indications",
"code" : "disease-or-histology"
},
"valueCodeableConcept" : {
"text" : "Collecting Duct/Medullary Subtypes"
}
},
{
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString" : "B"
}],
"code" : {
"system" : "http://terminology.hl7.org/CodeSystem/usage-context-type",
"code" : "focus"
},
"valueCodeableConcept" : {
"text" : "Kidney Cancer – Collecting Duct/Medullary Subtypes - Metastatic"
}
}],
"copyright" : "All rights reserved.",
"approvalDate" : "2016-07-27",
"lastReviewDate" : "2016-07-27",
"author" : [{
"name" : "Lee Surprenant"
}],
"relatedArtifact" : [{
"type" : "derived-from",
"display" : "NCCN Guidelines for Kidney Cancer. V.2.2016",
"document" : {
"url" : "http://www.example.org/professionals/physician_gls/PDF/kidney.pdf"
}
},
{
"type" : "citation",
"_type" : {
"extension" : [{
"url" : "http://example.org/fhir/regimenReferenceType",
"valueCode" : "a"
}]
},
"citation" : "Oudard S, et al. J Urol. 2007;177(5):1698-702",
"document" : {
"url" : "http://www.ncbi.nlm.nih.gov/pubmed/17437788"
}
}],
"action" : [{
"selectionBehavior" : "exactly-one",
"action" : [{
"selectionBehavior" : "all",
"action" : [{
"groupingBehavior" : "sentence-group",
"selectionBehavior" : "exactly-one",
"action" : [{
"id" : "cycle-definition-1",
"textEquivalent" : "21-day cycle for 6 cycles",
"timingTiming" : {
"repeat" : {
"count" : 6,
"duration" : 21,
"durationUnit" : "d"
}
},
"action" : [{
"id" : "action-1",
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle",
"extension" : [{
"url" : "day",
"valueInteger" : 1
},
{
"url" : "day",
"valueInteger" : 8
}]
}],
"textEquivalent" : "Gemcitabine 1250 mg/m² IV over 30 minutes on days 1 and 8",
"definitionCanonical" : "#1111"
},
{
"id" : "action-2",
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle",
"extension" : [{
"url" : "day",
"valueInteger" : 1
}]
}],
"textEquivalent" : "CARBOplatin AUC 5 IV over 30 minutes on Day 1",
"relatedAction" : [{
"targetId" : "action-1",
"relationship" : "concurrent-with-start"
}],
"definitionCanonical" : "#2222"
}]
}]
}]
}]
}]
}
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.
FHIR ®© HL7.org 2011+. FHIR R5 hl7.fhir.core#5.0.0 generated on Sun, Mar 26, 2023 15:25+1100.
Links: Search |
Version History |
Contents |
Glossary |
QA |
Compare to R4 |
Compare to R4B |
|
Propose a change